Abstract 3845
Background
For colorectal liver metastases (CRLM), some key prognostic factors— KRAS/NRAS/BRAF, location of primary tumor, and CA19-9—were identified for recurrence and survival but were rarely included in prognostic scoring system analysis. Besides, tumor burden score (TBS) is a prognostic indicator capturing the cumulative impact CRLM size and CRLM number, but TBS does not take spatial factor—unilobar or bilobar metastasis—into account.
Methods
787 patients undergoing hepatic resection of CRLM were included and were divided into training and validation groups. Modified TBS (mTBS) was established by a mathematical equation (parameters were CRLM size, CRLM number, and unilobar/bilobar metastasis). In the training group, the Cox proportional hazards model was used to identify independent predictors of prognosis; these factors were combined into the Comprehensive Evaluation of Recurrence Risk (CERR) score. The score was compared with Fong score and “Genetic and Morphological Evaluation” (GAME) score and validated in the validation group. Some indices (including C-index, iAUC, Akaike information criterion, net reclassification index, and integrated discrimination improvement) were calculated to compare the discriminatory capacities of three prognostic scoring systems.
Results
mTBS (AUC 0.617) out-performed TBS (AUC 0.568) in predicting recurrence-free survival (RFS) (P = 0.006). Five preoperative predictors of worse RFS were identified and were incorporated into CERR score: KRAS/NRAS/BRAF mutated tumor (1 point); node-positive primary (1 point); extrahepatic disease (1 point); CEA >200 ng/ml or CA19-9 >200 U/mL (1 point); mTBS between 5 and 11 (1 point) or 12 and over (2 points). Patients undergoing hepatectomy for CRLM were stratified by CERR score into risk groups: high-risk group (CERR score 4 or more) had a 3-year RFS rate of 9.77%; medium-risk group (CERR score 2-3) had a 3-year RFS rate of 21.96%; low-risk group (CERR score 0-1) had a 3-year RFS rate of 39.90%. The validation group showed that the discriminatory capacity of the CERR score was superior to that of the Fong score and the GAME score.
Conclusions
The CERR score is a prognostic tool that can be used to determine optimal clinical management strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital, Fudan University, Shanghai, China.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2840 - Effects of Aerobic and Resistance Exercise on Android:Gynoid Fat Ratio in Breast Cancer Survivors
Presenter: Christina Dieli-Conwright
Session: Poster Display session 2
Resources:
Abstract
869 - Impact of Education for Breast self examination in Rural Indian Women on Early Detection - results of POC study
Presenter: Sneha Parchuri
Session: Poster Display session 2
Resources:
Abstract
1951 - Breast cancer incidence and survival in renal transplant patients: 35-year experience
Presenter: Michalis Kontos
Session: Poster Display session 2
Resources:
Abstract
2017 - The changing landscape of breast cancer incidence after treatment for Hodgkin’s disease
Presenter: Amelia Benjamin
Session: Poster Display session 2
Resources:
Abstract
1780 - Number of deliveries as a prognostic factor in different breast cancer subtypes
Presenter: Anniina Jääskeläinen
Session: Poster Display session 2
Resources:
Abstract
4650 - Effects of supervised and adapted exercise program in the quality of life and strength of breast cancer survivors: MAMA MOVE Gaia trial
Presenter: Ana Joaquim
Session: Poster Display session 2
Resources:
Abstract
4962 - Study On the Socioeconomic and Clinical Factors Affecting the Proportion of Breast Conserving Surgery in Chinese Women Breast Cancer
Presenter: Jin Zhang
Session: Poster Display session 2
Resources:
Abstract
5451 - Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program?
Presenter: Marco Giavarra
Session: Poster Display session 2
Resources:
Abstract
888 - The value of genetic counselling in breast cancer genetic testing and clinical management
Presenter: Vicki Kiesel
Session: Poster Display session 2
Resources:
Abstract
4005 - Elderly patients in the Japanese Breast Cancer Registry
Presenter: Masataka Sawaki
Session: Poster Display session 2
Resources:
Abstract